|Full name ||European Research Infrastructure on Highly Pathogenic Agents|
|Operational status||implementation phase: partial operable|
|Director General||tba in September 2017|
|RI member countries ||FR, PT, SE|
|Contact||Diana Stepanyan, diana.stepanyan-yerdamian [at] inserm.fr; |
Hervé Raoul herve.raoul [at] inserm.fr
This sections provides an overview on the national subsidiaries of the RI.
|Inserm||Contact: Hervé Raoul, herve.raoul [at] inserm.fr |
|INSA||Contact: Sofia Nuncio, sofia.nuncio [at] insa.min-saude.pt |
|FOHM||Contact: Andreas Brave, |
andreas.brave [at] folkhalsomyndigheten.se
Description of the organisation
ERINHA is a pan-European Research distributed research infrastructure on ESFRI roadmap dedicated to the study of highly infectious emerging and re-emerging diseases classified as Risk Group 4 (RG4). It brings together European high containment and complementary research facilities and expertise required to perform cutting-edge research in shorter timeframes. ERINHA provides access to its state of art BSL-4 laboratories and complementary capacities and expertise to perform excellence orientated in-vitro and in-vivo research projects, trainings and advise. A wide range of capabilities and functions from high basic research laboratory capacities to NHP modeling research will be provided by ERINHA, as well as expertise of senior scientists and access to complementary functions (from BSL1 to BSL4, genomics, proteomics etc.).
ERINHA produces the ideal environment to facilitate coordination of research on risk group 4 (RG4) agents in Europe. The infrastructure will contribute to the enhancement of the European and global capacity, capability and emergency preparedness in the response to global outbreaks.
A list of services offered by ERINHA will be provided soon.